4//SEC Filing
Dries Robert E. 4
Accession 0001209191-17-064757
CIK 0001388195other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 4:58 PM ET
Size
10.3 KB
Accession
0001209191-17-064757
Insider Transaction Report
Form 4
Transactions
- Award
Performance share unit
2017-12-07+28,226→ 28,226 totalExercise: $0.00→ Common Stock, par value $0.01 (28,226 underlying) - Disposition to Issuer
Common Stock, $0.01 par value
2017-12-07$29.25/sh−28,226$825,611→ 0 total - Disposition to Issuer
Performance share unit
2017-12-07−28,226→ 0 totalExercise: $0.00→ Common Stock, par value $0.01 (28,226 underlying)
Footnotes (2)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent.
- [F2]Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) each share of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (ii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration.
Documents
Issuer
PharMerica CORP
CIK 0001388195
Entity typeother
Related Parties
1- filerCIK 0001682571
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 4:58 PM ET
- Size
- 10.3 KB